TAKEDA PHARMACEUTICAL CO LTD ADR (NYSE: TAK)

TAKEDA PHARMACEUTICAL CO LTD ADR

NYSE: TAK (Takeda Pharmaceutical Company L)

Last update: 28 Oct, 4:32AM

14.17

0.16 (1.14%)

Add to watchlist

Previous Close	14.01
Open	14.17
Volume	3,277,444
Avg. Volume (3M)	3,470,693
Market Cap	45,067,616,256

Price / Earnings (TTM)	50.61
Price / Earnings (Forward)	14.27
Price / Sales	1.53
Price / Book	0.980

52 Weeks Range	12.80 (-9%) — 15.69 (10%)
Earnings Date	30 Oct 2025
TTM Dividend Yield	4.61%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - Specialty & Generic (US)	Bullish	Mixed
	Drug Manufacturers - Specialty & Generic (Global)	Bullish	Mixed
Stock	Takeda Pharmaceutical Company L	Mixed	Mixed

AIStockmoo Score

-1.0

Analyst Consensus	2.0
Insider Activity	NA
Price Volatility	-1.0
Technical Moving Averages	-2.5
Technical Oscillators	-2.5
Average	-1.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
TAK	45 B	4.61%	50.61	0.980
ZTS	64 B	0.99%	24.76	13.04
HLN	42 B	1.27%	20.44	1.85
RDY	12 B	54.73%	18.09	2.97
TEVA	23 B	-	-	3.37
BHC	2 B	-	23.46	-

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Investment Style	Large Core
% Held by Insiders	0.01%
% Held by Institutions	2.30%

Ownership

Name	Date	Shares Held
Managed Asset Portfolios, Llc	30 Jun 2025	1,488,843

No data within this time range.

Date	Type	Details
03 Nov 2025	Announcement	New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
30 Oct 2025	Announcement	Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
27 Oct 2025	Announcement	HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
21 Oct 2025	Announcement	Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
21 Oct 2025	Announcement	HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry
23 Sep 2025	Announcement	20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
16 Sep 2025	Announcement	Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
11 Sep 2025	Announcement	Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
08 Sep 2025	Announcement	Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
05 Sep 2025	Announcement	U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

TTM Dividend Yield	4.61%
5Y Average Dividend Yield	3.39%
Payout Ratio	289.45%

Ex Date	Announcement Date	Payment Date	Details
30 Mar 2023	15 Mar 2023	10 Jul 2023	0.30996 Cash
29 Sep 2022	13 Sep 2022	12 Dec 2022	0.329553 Cash
30 Mar 2022	04 Mar 2022	11 Jul 2022	0.330062 Cash
29 Sep 2021	-	13 Dec 2021	0.396898 Cash
30 Mar 2021	15 Mar 2021	12 Jul 2021	0.406627 Cash
29 Sep 2020	-	11 Dec 2020	0.430533 Cash
30 Mar 2020	-	06 Jul 2020	0.419053 Cash
27 Sep 2019	09 Sep 2019	12 Dec 2019	0.411118 Cash
28 Mar 2019	16 Mar 2019	10 Jul 2019	0.417168 Cash
26 Sep 2018	-	13 Dec 2018	0.395501 Cash
27 Mar 2018	-	09 Jul 2018	0.40643 Cash
27 Sep 2017	-	11 Dec 2017	0.39946 Cash
29 Mar 2017	-	10 Jul 2017	0.39892 Cash
28 Sep 2016	-	12 Dec 2016	0.392415 Cash
29 Mar 2016	-	11 Jul 2016	0.43705 Cash
28 Sep 2015	-	11 Dec 2015	0.365323 Cash
27 Mar 2015	-	09 Jul 2015	0.365289 Cash
25 Sep 2014	-	11 Dec 2014	0.378342 Cash
26 Mar 2014	-	10 Jul 2014	0.443655 Cash
25 Sep 2013	-	12 Dec 2013	0.436978 Cash
26 Mar 2013	-	08 Jul 2013	0.457131 Cash
25 Sep 2012	-	13 Dec 2012	0.545983 Cash
27 Mar 2012	-	09 Jul 2012	0.563768 Cash
27 Sep 2011	-	12 Dec 2011	0.578629 Cash
28 Mar 2011	-	07 Jul 2011	0.555761 Cash
27 Sep 2010	-	13 Dec 2010	0.533229 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2023	0.310	1	2.17
2022	0.660	2	4.23
2021	0.804	2	5.90
2020	0.850	2	4.67
2019	0.828	2	4.20
2018	0.802	2	4.77
2017	0.798	2	2.81
2016	0.829	2	3.99
2015	0.731	2	2.92
2014	0.822	2	3.96
2013	0.894	2	3.88
2012	1.11	2	5.00
2011	1.13	2	5.15
2010	0.533	1	2.19
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	2.36%
Operating Margin (TTM)	11.68%
Diluted EPS (TTM)	0.230
Quarterly Revenue Growth (YOY)	0.20%
Quarterly Earnings Growth (YOY)	-77.50%

Total Debt/Equity (MRQ)	73.36%
Current Ratio (MRQ)	1.01
Operating Cash Flow (TTM)	1.06 T
Levered Free Cash Flow (TTM)	735.62 B

Return on Assets (TTM)	2.40%
Return on Equity (TTM)	1.52%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)